Industry Report - Drug Delivery Partnership Strategies.pdf
《Industry Report - Drug Delivery Partnership Strategies.pdf》由会员分享,可在线阅读,更多相关《Industry Report - Drug Delivery Partnership Strategies.pdf(101页珍藏版)》请在三一文库上搜索。
1、 1 Drug Delivery Partnership Strategies Case studies in effective licensing, collaboration, and therapeutic differentiation Reference Code: BI00019-008 Publication Date: March 2012 2 About the author Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services t
2、o the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School. Delphi Pharma provides strategic, financial and marketbased solutions to clients, focusing primarily on the portfol
3、io management, licensing, and pricing and reimbursement functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. Disclaimer Copyright 2012 Informa Ltd This report
4、is published by Informa (the Publisher). This report contains information from reputable sources and although reasonable efforts have been made to publish accurate information, you assume sole responsibility for the selection, suitability and use of this report and acknowledge that the Publisher mak
5、es no warranties (either express or implied) as to, nor accepts liability for, the accuracy or fitness for a particular purpose of the information or advice contained herein. The Publisher wishes to make it clear that any views 3 or opinions expressed in this report by individual authors or contribu
6、tors are their personal views and opinions and do not necessarily reflect the views/opinions of the Publisher. Table of Contents About the author 2 Disclaimer 2 Executive summary 9 An introduction to drug delivery partnerships 9 The drug delivery value chain 9 Partnering trends in drug delivery tech
7、nology 10 Drug delivery partnerships for lifecycle management 11 Drug delivery partnerships for novel drug delivery applications 12 Drug delivery partnerships for complex development compounds 13 Best practices for effective drug delivery partnering 14 Chapter 1 An introduction to drug delivery part
8、nerships 16 Summary 16 Introduction 17 Report objectives 17 Report methodology 17 Report structure 18 Chapter 2 The drug delivery value chain 20 Summary 20 Introduction 21 Drug delivery technologies in context 21 4 Oral drug delivery 22 Topical/transdermal drug delivery 23 Transmucosal drug delivery
9、 23 Inhalation drug delivery 23 Injection drug delivery 24 Other novel drug delivery technologies 24 Platform versus applied technologies 25 Drug delivery development 26 Drug delivery productivity 26 Branded drug delivery products 27 Generic drug delivery products 31 In-house versus external technol
10、ogy development 34 The drug delivery partnership model 35 Drug delivery partnerships for lifecycle management 36 Drug delivery partnerships for novel drug delivery applications 37 Drug delivery partnerships for complex development compounds 38 Chapter 3 Partnering trends in drug delivery technology
11、40 Summary 40 Introduction 41 Global partnering trends 41 Product versus technology 42 Partnering trends by level of collaboration 46 Trends by partners 49 Partnering trends in context 53 Future partnering trends 57 Chapter 4 Drug delivery partnerships for lifecycle management 60 5 Summary 60 Introd
12、uction 61 Market expansion and generic defense strategies 61 Case study: Suboxone sublingual film line extension 61 Case study: Vyteris repositions as a contract research organization 63 Case study: Mylan acquires dry-powder delivery technology from Pfizer 65 Key challenges and critical success fact
13、ors 66 Timing versus flexibility 66 Proof of concept versus risk management 67 Collaboration versus assigned responsibilities 67 Additional expert insights 68 Chapter 5 Drug delivery partnerships for novel drug delivery applications 69 Summary 69 Introduction 70 Competitive market differentiation st
14、rategies 70 Case study: Intermezzo delivers new indication 70 Case study: Flutiform partner runs out of patience 72 Case study: Alkermes acquires a new position in drug delivery space 75 Key challenges and critical success factors 76 Partner funding versus partner expertise 77 Focused application ve
15、rsus consolidated portfolio 77 Common objectives versus competitive repositioning 78 Additional expert insights 78 Chapter 6 Drug delivery partnerships for complex development compounds 81 6 Summary 81 Introduction 82 Innovative drug development strategies 82 Case study: Vecturas partnering-based ev
16、olution down-stream 82 Case study: Alkermes delivers game changing value in tripartite development partnership 84 Case study: ThermoDoxs drug delivery device, clinical and commercial partnering network 86 Key challenges and critical success factors 88 Technology value versus partnering rewards 88 Co
17、mmercial validation versus evolving down-stream 89 Partner of choice versus complementary partner objectives 89 Additional expert insights 89 Chapter 7 Best practices for effective drug delivery partnering 92 Summary 92 Introduction 93 Maximizing therapeutic value 93 Delivering effective differentia
18、tion 94 Enabling complex development programs 96 Strategic partnering 97 Appendix 100 Methodology 100 MedTrack partnering deals database 100 Primary research 100 Glossary/Abbreviations 101 Bibliography/References 101 7 Table of figures Figure 1: Drug delivery product approvals in US, 2001-10 27 Figu
19、re 2: US branded drug delivery product sales in top 200 products, 2009-10 28 Figure 3: Branded drug delivery product cost/prescription in US, 200910 29 Figure 4: Leading branded drug delivery products by US sales, 2010 30 Figure 5: Generic drug delivery product sales in US, 200910 32 Figure 6: Gener
20、ic drug delivery product cost/prescription in US, 200910 33 Figure 7: Leading generic drug delivery products by US sales, 2010 34 Figure 8: Drug delivery partnerships for lifecycle management 37 Figure 9: Drug delivery partnerships for novel drug delivery applications 38 Figure 10: Drug delivery par
21、tnerships for complex development compounds 39 Figure 11: Drug delivery partnership deals, 200010 42 Figure 12: Product versus technology-based drug delivery deals, 200010 43 Figure 13: Product versus technology-based drug delivery deal values, 200010 44 Figure 14: Leading drug delivery partnership
22、technologies, 200110 46 Figure 15: Drug delivery partnerships by degree of collaboration, 200010 48 Figure 16: Drug delivery partnership values by degree of collaboration, 200010 49 Figure 17: Drug delivery partnerships by partner, 200010 50 Figure 18: Drug delivery partnership values by partner, 20
23、0010 51 Figure 19: Top 10 pharma companies by number of drug delivery deals, 2000H1 2011 52 Figure 20: Leading drug delivery partners by number of deals, 2000H1 2011 53 8 Table of tables Table 1: Drug delivery development and approval 26 Table 2: Branded drug delivery product prescriptions in US, 20
24、0910 28 Table 3: Leading branded drug delivery products by US sales, 2010 31 Table 4: Generic drug delivery product prescriptions in US, 2009-10 32 Table 5: Key drug delivery partnership deals, 200011 45 9 Executive summary An introduction to drug delivery partnerships ? While many delivery technolo
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Industry Report Drug Delivery Partnership Strategies
链接地址:https://www.31doc.com/p-3771666.html